Related Experiment Video

Updated: Jun 17, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Molecular basis of myelodysplastic/myeloproliferative neoplasms

Andreas Reiter, Rosangela Invernizzi, Nicholas C P Cross

    Haematologica
    |December 10, 2009
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia
    06:33

    Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

    Published on: November 10, 2023

    Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
    12:05

    Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

    Published on: November 3, 2018

    Related Experiment Videos

    Last Updated: Jun 17, 2026

    Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
    06:39

    Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

    Published on: October 3, 2018

    Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia
    06:33

    Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

    Published on: November 10, 2023

    Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
    12:05

    Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

    Published on: November 3, 2018

    Related Concept Videos

    Abnormal Proliferation02:23

    Abnormal Proliferation

    Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
    Differentiation of Common Myeloid Progenitor Cells01:15

    Differentiation of Common Myeloid Progenitor Cells

    Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
    Lineage Commitment01:21

    Lineage Commitment

    Commitment is the  process whereby stem cells:

    Articles linked to this work by shared authors, journal, and citation graph.

    Subtype-specific outcome after allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis: a registry study of the European competence network on mastocytosis.

    Experimental hematology & oncology·2026

    Biological functions and clinical efficacy of IL-5/IL-5Rα-targeted therapies across eosinophilia-associated diseases.

    Frontiers in immunology·2026

    Outcomes and prognostic factors in patients with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry study.

    Journal of hematology & oncology·2026

    Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years.

    The Journal of allergy and clinical immunology·2026

    Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial.

    Nature medicine·2026

    Myeloid Neoplasms With a t(5;12)(q31;p13) and an Associated ETV6::ACSL6 Gene Fusion Are Diagnostically Challenging and Have a Poor Prognosis.

    Genes, chromosomes & cancer·2026

    Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study.

    Haematologica·2026

    Surveying survival: benchmarking acute myeloid leukemia outcomes without transplant.

    Haematologica·2026

    Measurable residual KMT2A partial tandem duplication before allogeneic stem cell transplantation in acute myeloid leukemia.

    Haematologica·2026

    Normal platelet function in a patient with ARHGEF1 deficiency.

    Haematologica·2026

    Bone marrow biopsy characteristics at nadir after intensive induction therapy do not predict outcomes in adult acute myeloid leukemia patients: an analysis of ECOG-ACRIN clinical trials.

    Haematologica·2026

    Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma.

    Haematologica·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us